Catalyst Pharmaceuticals, Inc.

NASDAQ:CPRX

Biotechnology

Healthcare
$31.49 -0.03%

-$0.01 today

Market cap
$3.85B
Beta
0.74
P/E (TTM)
17.3
EPS (TTM)
$1.81
52W Low $19.05High $32.56

Volume 0.00M

Average 2.17M

CPRX Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Catalyst Pharmaceuticals, Inc.NASDAQ: CPRX

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin widens to 42.7%

Net margin was 42.7% in Q1 FY2026, up 2.5 pp from a year earlier. On a trailing-twelve-month basis it was 37.1%, up 0.2 pp year over year. Over 3 fiscal years it narrowed by 2.4 pp.

Context

  • Net margin widened in 2 of the last 3 fiscal years.

What to watch

Whether net margin reaches the consensus estimate from 2 analysts of 39.1% for the fiscal year ending Dec 2026, up from 36.4% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
42.7%+8.1 pp QoQ
Last fiscal yearDec 2025
36.4%+3.1 pp YoY
LTMMar 2026
37.1%+0.2 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+2.5 pp+3.5 pp+1.0 pp
1 year+3.1 pp+2.7 pp-0.4 pp
3 years-2.4 pp+4.9 pp+7.3 pp
5 years+1.0 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
36.4%
Year-over-year change
+3.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How CPRX compares with its peers on the latest reported figures

  • CPRX's LTM Mar 2026 net margin of 37.1% is the highest of the 8 companies compared; the peer median is -62.2%.
  • Its year-over-year change of +0.2 pp is the 6th highest of 7, against a peer median of +49.7 pp.
  • Over three fiscal years its change of -2.4 pp compares with a peer median of +74.9 pp.
CPRX Competitors Peer median
Net Margin for CPRX and competitors
Company Period LTM level YoY 3-year change
CPRXCatalyst Pharmaceuticals, Inc.LTM Mar 202637.1% +0.2 pp-2.4 pp
KNSAKiniksa Pharmaceuticals, Ltd.LTM Jun 20269.6% +8.7 pp-74.6 pp
ADPTAdaptive Biotechnologies CorporationLTM Jun 2026-20.7% +38.3 pp+86.5 pp
BEAMBeam Therapeutics Inc.LTM Jun 2026-54.7% +606.6 pp+417.3 pp
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026-62.2% +4313.7 pp+63.2 pp
AGIOAgios Pharmaceuticals, Inc.LTM Mar 2026-639.8% -2438.1 pp+863.8 pp
RXRXRecursion Pharmaceuticals, Inc.LTM Jun 2026-945.9% +61.1 pp-259.8 pp
SRRKScholar Rock Holding CorporationLTM Sep 2026-72563.2% ——
MLYSMineralys Therapeutics, Inc.FY2025— ——
Peer median (excluding CPRX) -62.2%+49.7 pp+74.9 pp

Competitors are the stored peer set for CPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue140.83M214.2M398.2M491.73M588.99M
Cost of Revenue21.88M34.39M51.97M68.85M87.25M
Gross Profit118.95M179.81M346.24M422.89M501.74M
Gross Margin84.5%83.9%86.9%86.0%85.2%
Research & Development16.94M19.79M93.15M12.65M12.71M
Selling, General & Admin49.63M57.09M133.71M177.74M193.75M
Operating Expenses66.56M77.97M259.43M227.77M243.96M
Depreciation & Amortization192K1.24M32.88M37.77M37.87M
EBITDA52.86M105.96M127.39M254.04M321.39M
EBITDA Margin37.5%49.5%32.0%51.7%54.6%
Operating Income52.39M101.84M86.81M195.12M257.78M
Operating Margin37.2%47.5%21.8%39.7%43.8%
Interest Income00016.06M0
Interest Expense00000
Other Income / Expenses282K2.88M7.7M21.14M25.74M
Income Before Tax52.67M104.72M94.51M216.26M283.52M
Pre-Tax Margin37.4%48.9%23.7%44.0%48.1%
Income Tax Expense13.19M21.64M23.1M52.37M69.19M
Net Income39.48M83.08M71.41M163.89M214.33M
Net Margin28.0%38.8%17.9%33.3%36.4%
EPS (Basic)0.380.800.671.381.75
EPS (Diluted)0.370.750.631.311.68
Weighted Avg Shares103.38M103.37M106.28M118.46M122.29M
Weighted Avg Shares (Diluted)107.8M111.38M113.75M124.94M127.26M

Catalyst Pharmaceuticals, Inc.

NASDAQ:CPRX

Intrinsic Alpha fair value

Locked

Current Price

$31.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.